Desmoid Tumor Drug Shows Promise

Shares of Immunome saw a significant increase following the announcement of positive clinical results for varegacestat, a treatment for desmoid tumors. This destructive disease affects 1,000 to 1,650 people annually in the U.S., causing debilitating physical and emotional distress.

The Phase 3 trial for varegacestat achieved its primary endpoint, demonstrating an 84% reduction in the risk of disease progression or death. All key secondary endpoints, including tumor volume and pain reduction, were also met. The drug was generally well-tolerated by participants.

Immunome intends to file a New Drug Application with the U.S. Food and Drug Administration in the second quarter of 2026. Based on these encouraging findings, varegacestat could potentially become the best-in-class, once-daily oral medicine for patients with desmoid tumors.